01:45 PM EST, 01/30/2025 (MT Newswires) -- Alpha Modus ( AMOD ) Chief Executive William Alessi emphasized Thursday the company's "strong" fundamentals and an "ongoing" growth strategy amid "uninformed speculation" by certain market participants.

"The recent sell-side activity targeting AMOD stock appears to be driven by misconceptions and a lack of understanding about our business and long-term strategy coupled with the 'de-SPAC norm,'" Alessi said in a company statement.

Shares soared 133% as intraday trading volume surged to over 115.9 million from a daily average of about 66,000.

Tectonic Therapeutic ( TECX ) shares surged 109% after the company said Thursday a phase 1b trial showed that a single intravenous dose of TX45 resulted in "meaningful improvements" in left ventricular function and pulmonary hemodynamics.

Over 4.3 million shares traded intraday versus a daily average of nearly 144,000.

Alterity Therapeutics ( ATHE ) said Thursday its ATH434 lead candidate demonstrated 48% slowing of clinical progression in a phase 2 clinical trial in patients with early-stage multiple system atrophy.

Shares jumped 50% as intraday trading volume catapulted to more than 20.6 million from a daily average of about 71,000.

Price: 3.59, Change: +2.05, Percent Change: +133.12